Keywords: Multiple sclerosis, Tysabri, Gilenya, Aubagio, Novartis, Biogen Idec, Elan, Sanofi, Decision Resources

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch

Article | 28 September 2012

Print This

The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan’s (NYSE: ELN) Tysabri (natalizumab). has increased significantly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in